{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:56:22Z","timestamp":1790751382499,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intraperitoneal metastasis is a frequent progression in colon cancer, highlighting the critical need for enhanced therapeutic approaches. Oncolytic virus (OV) therapy has emerged as a promising immunotherapeutic strategy. The combination of OVs with immune checkpoint inhibitors (ICIs) has demonstrated an enhanced anti-tumor response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We generated the intraperitoneal-subcutaneous bilateral colon cancer xenograft model to simulate intraperitoneal metastatic colon cancer, and evaluated the systemic antitumor efficacy of the oncolytic HSV-1 virus VT1092M in combination with ICIs (anti-PD-L1 antibody and anti-CTLA-4 antibody).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>\n                      Intraperitoneal administration of VT1092M markedly suppressed intraperitoneal cancer progression and enhanced the superior antitumor efficacy of ICIs immunotherapy in murine intraperitoneal metastatic colon cancer. Notably, treatment of VT1092M combined with anti-CTLA-4 antibody could eliminate both intraperitoneal metastases and subcutaneous tumors, while also inhibiting the formation of peritoneal blood vessels and malignant ascites. The synergistic combination of VT1092M and anti-CTLA-4 elicited potent intraperitoneal and systemic antitumor immunity, culminating in durable, tumor-specific memory that significantly prolonged survival in mice with colorectal intraperitoneal metastases compared to either monotherapy. Mechanistically, the combination therapy activates the anti-tumor immune environment within the peritoneal cavity, leading to a significant increase in tumoricidal CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and M1 macrophages, as well as the reprogramming of transcriptional signatures associated with the tumor immune response within the tumor microenvironment. Ultimately, intraperitoneal immunotherapy with VT1092M enhances the efficacy of immune checkpoint blockade in suppressing intraperitoneal metastatic colorectal cancer and induces durable tumor-specific immune memory, thereby exerting substantial anti-tumor effects. This finding highlights the potential of synergistically combining oncolytic viruses with ICIs to advance immunotherapeutic strategies for intraperitoneal metastatic colorectal cancer.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1926207","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:06:54Z","timestamp":1790748414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic virus VT1092M synergizes with immune checkpoint inhibitors against intraperitoneal metastases of colorectal cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Zongfeng","family":"Hu","sequence":"first","affiliation":[{"name":"School of Pharmacy, Yantai University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Yuan","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Yantai University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhen","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Yantai University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Yantai University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing WellGene Company, Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing WellGene Company, Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyang","family":"Sun","sequence":"additional","affiliation":[{"name":"Beijing WellGene Company, Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Tian","sequence":"additional","affiliation":[{"name":"Beijing WellGene Company, Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixuan","family":"Xue","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Yantai University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Yantai University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Yantai University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitian","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Yantai University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianshuai","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing WellGene Company, Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Yantai University","place":["Yantai, Shandong, China"]},{"name":"Beijing WellGene Company, Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Yantai University","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.59","article-title":"Colorectal cancer drugs market","volume":"16","author":"Cassidy","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174464","article-title":"Current trends and future perspectives of nanomedicine for the management of colon cancer","volume":"910","author":"Wahab","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v11.i7.551","article-title":"TYMS\/KRAS\/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer","volume":"11","author":"Ntavatzikos","year":"2019","journal-title":"World J Gastrointest Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S273612","article-title":"Enteric-coated strategies in colorectal cancer nanoparticle drug delivery system","volume":"14","author":"Wathoni","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ans.15796","article-title":"Colorectal peritoneal metastases: pathogenesis, diagnosis and treatment options - an evidence-based update","volume":"90","author":"Narasimhan","year":"2020","journal-title":"Anz J Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","article-title":"Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients","volume":"29","author":"Halama","year":"2016","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0001","article-title":"Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic Malignancies","volume":"8","author":"Janakiram","year":"2016","journal-title":"Immunotherapy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s40265-014-0305-6","article-title":"Clinical impact of checkpoint inhibitors as novel cancer therapies","volume":"74","author":"Shih","year":"2014","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.03.020","article-title":"The evolutionary legacy of immune checkpoint inhibitors","volume":"86","author":"Kaushik","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","article-title":"Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/2326-6066.cir-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40169-018-0214-5","article-title":"Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials","volume":"7","author":"LaRocca","year":"2018","journal-title":"Clin Transl Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2021.06.005","article-title":"Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody","volume":"518","author":"Tian","year":"2021","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005640","article-title":"Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer","volume":"11","author":"Monge","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000857","article-title":"Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101287","article-title":"The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy","volume":"15","author":"Xie","year":"2022","journal-title":"Transl Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.imlet.2021.11.002","article-title":"The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma","volume":"241","author":"Zhu","year":"2022","journal-title":"Immunol Lett"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102020","article-title":"The oncolytic virus VT1092M and an anti-PD-L1 antibody synergize to induce systemic antitumor immunity in a murine bilateral tumor model","volume":"46","author":"Zhu","year":"2024","journal-title":"Transl Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"23671","DOI":"10.1038\/s41598-024-72888-w","article-title":"Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15\/IL-15R\u03b1 complex combined with oncolytic HSV-1-aPD1 targets colon cancer","volume":"14","author":"Hu","year":"2024","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-299","article-title":"Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo","volume":"9","author":"Tiffen","year":"2010","journal-title":"Mol Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1226","article-title":"Mapping and quantifying mammalian transcriptomes by RNA-Seq","volume":"5","author":"Mortazavi","year":"2008","journal-title":"Nat Methods"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903210","article-title":"IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms","volume":"184","author":"Sorensen","year":"2010","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-04-0081","article-title":"Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12","volume":"10","author":"Wong","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1307935110","article-title":"Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model","volume":"110","author":"Cheema","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02737","article-title":"CTLA-4 and PD-1 control of T-cell motility and migration: implications for tumor immunotherapy","volume":"9","author":"Brunner\u2010Weinzierl","year":"2018","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2016.1224666","article-title":"The current status of immunotherapy in peritoneal carcinomatosis","volume":"16","author":"Trohlein","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i35.12493","article-title":"Current treatment options for colon cancer peritoneal carcinomatosis","volume":"20","author":"Aoyagi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7150\/jca.32806","article-title":"STING signaling is a potential immunotherapeutic target in colorectal cancer","volume":"10","author":"Chon","year":"2019","journal-title":"J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.11.012","article-title":"Immunodivergence in metastatic colorectal cancer","volume":"34","author":"de Andrea","year":"2018","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40259-019-00367-0","article-title":"Oncolytic viruses: priming time for cancer immunotherapy","volume":"33","author":"Russell","year":"2019","journal-title":"BioDrugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004691","article-title":"Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors","volume":"10","author":"Su","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.971674","article-title":"The gamble between oncolytic virus therapy and IFN","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1926207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:06:55Z","timestamp":1790748415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1926207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1926207"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1926207","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1926207"}}